The goal of the research activities at the Laboratory of Molecular and Cellular Therapy (LMCT) is to develop innovative immunotherapy strategies. The strategies under development include (1) ex vivo and in vivo engineering of dendritic cells for immune activation and (2) engineering of the tumor microenvironment to facilitate antitumor immune responses. Technologies such as mRNA, lentiviral vectors and single domain antibodies (better known as nanobodies) are employed for these purposes. Strategies under development are extensively tested in preclinical in vitro models using cells of human and mouse origin as well as in mouse cancer models. Successful strategies are translated towards clinical applications in phase I/II trials.